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Aims Pulmonary arterial hypertension (PAH) is a devastating disease and treatment options are limited. Urocortin-2
(Ucn-2) has shown promising therapeutic effects in experimental and clinical left ventricular heart failure (HF). Our
aim was to analyse the expression of Ucn-2 in human and experimental PAH, and to investigate the effects of
human Ucn-2 (hUcn-2) administration in rats with monocrotaline (MCT)-induced pulmonary hypertension (PH).
....................................................................................................................................................................................................
Methods
and results
Tissue samples were collected from patients with and without PAH and from rats with MCT-induced PH. hUcn-2 (5
lg/kg, bi-daily, i.p., for 10 days) or vehicle was administered to male wistar rats subjected to MCT injection or to pul-
monary artery banding (PAB) to induce right ventricular (RV) overload without PAH. Expression of Ucn-2 and its
receptor was increased in the RV of patients and rats with PAH. hUcn-2 treatment reduced PAH in MCT rats, result-
ing in decreased morbidity, improved exercise capacity and attenuated pulmonary arterial and RV remodelling and
dysfunction. Additionally, RV gene expression of hypertrophy and failure signalling pathways were attenuated. hUcn-2
treatment also attenuated PAB-induced RV hypertrophy.
....................................................................................................................................................................................................
Conclusions Ucn-2 levels are altered in human and experimental PAH. hUcn-2 treatment attenuates PAH and RV dysfunction in
MCT-induced PH, has direct anti-remodelling effects on the pressure-overloaded RV, and improves pulmonary vas-
cular function.
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1. Introduction
Pulmonary arterial hypertension (PAH) is a rare and severe condition
characterized by intense pulmonary vascular remodelling, vasoconstric-
tion, endothelial dysfunction, inflammation and in situ thrombosis, leading
to elevated pulmonary vascular resistance (PVR) and right ventricular
(RV) failure.1,2 Available therapies decrease patients’ risk of short-term
mortality and clinical worsening3; however, long-term prognosis remains
poor.4 RV function is the main predictor of the outcome in PAH5 and
thus new therapies should also protect against RV maladaptation and
failure.6
Urocortin-2 (Ucn-2) is an endogenous vasoactive peptide of the
corticotropin-releasing hormone (CRH) family that binds with high affin-
ity to the Type 2 CRH receptor (CRHR2), which is expressed abun-
dantly in the cardiovascular system.7 Ucn-2 promotes important cardiac
haemodynamic effects, including vasodilation and positive cardiac
inotropic, chronotropic, and lusitropic actions.8 Additionally, the
Ucn-2/CRHR2 system exhibits cardioprotective actions, preventing cell
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necrosis and apoptosis9,10 and decreasing infarct size in the rat heart
after ischaemia-reperfusion injury.10–12
Acute Ucn-2 administration in experimental heart failure (HF) has
beneficial haemodynamic effects, while suppressing adverse neurohor-
monal responses,13,14 whereas chronic treatment after experimental
myocardial infarction improves cardiac function and structure.15 In
patients with stable congestive16 and acute decompensated HF,17 intra-
venous Ucn-2 produces an increase in cardiac output (CO) and left ven-
tricular (LV) ejection fraction (EF) in association with a reduction in
systemic vascular resistance, blood pressure and cardiac work. Plasma
levels of Ucn-2 are elevated in patients with abdominal aortic aneur-
ysm,18 LV systolic dysfunction with coronary artery disease19 and non-
ischaemic dilated cardiomyopathy,20 suggesting a potential role of Ucn-2
as a biomarker in heart disease. Additionally, plasma concentrations of
N-terminal-proUcn-2 are independently and inversely related to 2-year
survival in HF.21
Ucn-2 is reported to induce vasorelaxation of human coronary
arteries independently of the endothelium,22 while in healthy volun-
teers, arterial vasodilatation appears to be at least partly mediated by
endothelial nitric oxide.23 Ucn-2 is also associated with abdominal
aortic aneurysm and mediates anti-proliferative effects on vascular
smooth muscle cells.18 Moreover, Ucn-2 has sustained blood pressure–
lowering effects in hypertensive rats and attenuates hypertension-
induced LV hypertrophy and dysfunction,24 suggesting a novel thera-
peutic approach for systemic arterial hypertension.
Considering the need for new cardiac-directed drugs in PAH, and the
cardioprotective effects of Ucn-2 in HF, we hypothesized that Ucn-2
might have a potential role in the treatment of established PAH. In this
study, we evaluated the expression of Ucn-2/CRHR2 signalling in human
and experimental PAH, and investigated the functional and structural
effects of chronic human Ucn-2 (hUcn-2) treatment on the heart and
pulmonary vessels of rats with monocrotaline (MCT)-induced pulmo-
nary hypertension (PH). To distinguish cardiac-specific actions from
effects on the pulmonary vasculature, hUcn-2 treatment was also studied
in an experimental model of pressure overload by pulmonary artery
banding (PAB), which results in RV loading without PAH.
2. Methods
All patients or their legal representatives (in the case of autopsy) gave
informed consent before the beginning of the study in accordance to the
declaration of Helsinki, and institutional guidelines were approved by
Institut Universitaire de Cardiologie et de Pneumologie de Que´bec
(CER-20773). The usage of human tissues follow recommendations pub-
lished,25 in collaboration with the Institut Universitaire de Cardiologie et
de Pneumologie de Que´bec site of the Respiratory Health Network
tissue bank of the Fonds de recherche du Que´bec – Sante´ (FRQS)
(www.tissuebank.ca). All animal experiments were performed in accord-
ance with the recommendations of the Guide for the Care and Use of
Laboratory Animals, published by the US National Institutes of Health
(NIH Publication No. 85-23, Revised 2011), and were approved by the
ethical committee of the Faculty of Medicine of the University of Porto
and the Portuguese Foundation for Science and Technology, and certi-
fied by the Portuguese National Authority for Animal Health (PTDC/
DTP-FTO/0130/2012; 0421/000/000/2013). A detailed method section
is available in Supplementary material online.
2.1 Human samples
Human RV samples were collected from patients with and without PAH
(see Supplementary material online, Table S1) at the time of cardiac sur-
gery, heart transplantation or autopsy (within 3 h of death). Samples
were categorized according to clinical history and designated as compen-
sated RV (CRV) or RV failure (RVF).26 Blood samples were also col-
lected from PAH patients and age-matched controls.27
2.2 Animal study
PAH was induced as previously described.28 Seven-week-old male
Wistar rats (Charles River Laboratories, 180-200 g) randomly received
an injection of MCT (60 mg/kg, s.c., Sigma-Aldrich) or an equal amount
of vehicle. Two weeks after MCT/vehicle administration, animals were
further randomly divided to receive hUcn-2 (Bachem) at a dose of 5 lg/kg
(bi-daily, i.p.) or an equal amount of vehicle (0.9% NaCl) for 10 days,
resulting in four groups: Ctrl þ vehicle (C); Ctrlþ hUcn-2 (CU); MCTþ
vehicle (M); MCT þ hUcn-2 (MU). After the treatment period, animals
were submitted to exercise testing and echocardiographic and invasive
haemodynamic analysis, with subsequent sample collection for in vitro
functional studies, morphological, histological, and molecular analysis,
as detailed in Supplementary material online. To determine whether
MCT-induced PH was already present prior to therapy, a subgroup of ani-
mals underwent the same experimental protocol and was evaluated at an
earlier time point (14 days) (see Supplementary material online, Figures S7
and S8).
An additional subgroup of rats was subjected to PAB (16-gauge) or
sham procedure,29 where applying a pulmonary artery constriction
resulted in a degree of hypertrophy and RV overload identical to the
MCT-induced PH model (see Supplementary material online, Figure S6).
Two weeks after PAB, animals randomly received hUcn-2 or vehicle for
10 days, resulting in three groups: Shamþ vehicle (S); PABþ vehicle (B),
and PAB þ hUcn-2 (BU). Sampling was performed as in the MCT
protocol.
2.3 Survival analysis
The defined end-point for the survival analysis was a 20% loss of body
weight plus oedema/ascites and decreased movement. When this end-
point was reached, animals were euthanized with an anaesthetic over-
dose (sodium pentobarbital 100 mg/kg, Eutasil, CEVA). Only those ani-
mals reaching the end-point before evaluation at study-end were
considered valid and used in the survival analysis.
2.4 Exercise capacity test
Animal exercise capacity was tested on a close-chamber treadmill set
with electric stimulation (LE8710R, Columbus Instruments) coupled to a
gas analyser. Peak effort to assess maximal oxygen consumption
(VO2max)
30 and endurance tests31 were evaluated in different sets of ani-
mals, and were performed 13 and 23 days after PAH induction.
2.5 Echocardiography
Echocardiographic analysis,28 was performed 13 days (baseline) and 24
days after PAH induction. Animals were lightly anaesthetized (inhalation
of 8% sevofluorane for induction, and 2–3.5% for maintenance).
Echocardiographic evaluation was performed using a 15 MHz probe (GE
Healthcare) and a Acuson Sequoia C512 echocardiography system
(Siemens), for determination of pulmonary flow and RV structure.
1166 R. Ad~ao et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/article-abstract/114/8/1165/4951951 by U
niversidade do Porto user on 16 O
ctober 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
2.6 Invasive haemodynamic evaluation
Following echocardiographic evaluation, the animals were intubated and
ventilated. Using an open chest approach, as previously described in,28
pressure – volume catheters were introduced in the RV and LV
(SPR-869 and SPR-847, respectively, Millar Instruments). A flow probe
was implanted around the ascending aorta (MA2.5PSB, Transonic
Systems). Baseline and inferior vena cava occlusion recordings were
obtained, and a bolus injection of hypertonic saline was administered to
account for parallel conductance. Pressure and volume signals were con-
tinuously acquired (MPVS Ultra, Millar Instruments), digitally recorded
(PowerLab 16/30, ADInstruments), and analysed off-line (LabChart 7 Pro,
ADInstruments). Following anaesthetic overdose, blood samples were
taken, the animals exsanguinated and heart and lungs collected en bloc.
2.7 Morphometric and histological analysis
Following removal, the lungs, RV and LVþ septum (LV þ S) were care-
fully separated and weighed. Tibia length was measured for weight nor-
malization. RV and lung samples were collected, snap frozen in liquid
nitrogen, and stored at -80C. For mRNA quantification, samples were
submerged in RNA stabilization reagent (RNAlater, Qiagen), and for his-
tological analysis, samples were stored in buffered 10% formaldehyde.
2.8 Assessment of isolated pulmonary
artery endothelial function and
vascular acute analysis
As previously described in,28 second-generation pulmonary arteries
(200–400 mm diameter) were dissected from the left upper lobe of rats.
Arterial rings were isolated and mounted in a bath myograph system
(720 MO, DMT). Maximum tension development was assessed with 80
mM KCl solution. For the determination of the acute vasodilatory effects
of hUcn-2, arterial rings were contracted with phenylephrine (10-5 M),
and a dose response to hUcn-2 (10-9 to 5 10-7 M) or vehicle (ddH2O)
was performed. Maximal relaxation to hUcn-2 (Emax) and the concentra-
tion of hUcn-2 required for 50% of the maximal response (EC50) were
calculated. Pulmonary artery endothelial function was assessed by
attaining a dose–response curve to acetylcholine (10-9 to 10-5 M) after
pre-contraction with phenylephrine (10-5 M). Maximal relaxation to ace-
tylcholine and EC50 were calculated. Analysis was performed offline
(LabChart 7 Pro, ADInstruments).
2.9 In vitro studies in isolated skinned
cardiomyocytes
RV samples (stored at -80C) were defrosted in relax solution, and a
biopsy taken, subjected to mechanical disruption, and permeabilized with
0.1% Triton X-100. Under microscopic view (model 1X51, Olympus) and
through imaging software (VSL 900B, Aurora Scientific), a single cardio-
myocyte was attached to a force transducer (model 403 A, Aurora
Scientific) and a length controller (model 315 C-I, Aurora Scientific). Cell
length was digitally adjusted through custom-designed software (series
600 A digital controller, Aurora Scientific), and steady-state passive force
measured at increasing sarcomere lengths (1.8-2.3 mm). Force measure-
ments were normalized to each cardiomyocyte cross-sectional area
(CSA) and a minimum of three cells per animal measured.29
2.10 Quantitative RT-PCR, immunoblot-
ting, and enzyme-linked immunosorbent
assay
For human samples, total RNA was isolated from tissue using the
RNeasy micro kit according to the manufacturer’s instruction, and
mRNA reverse transcribed and amplified using one-step kit TaqMan
probes. qRT-PCR was performed with the ABI Prism 7900 Sequence
Detector (Applied Byosystems), and 18 s used as a housekeeping gene.
The relative expression level of Ucn-2 and CRHR2 was determined by
the 2-DCt *100.
For rat samples, total RNA was extracted using the RNeasy Mini Kit
according to manufacturer’s instructions, and relative mRNA expression
quantified by two-step Real-Time PCR (Step-One Applied Biosystems).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a
reference gene, and results presented in arbitrary units and normalized
for the control group. Primers used were designed in-house (see
Supplementary material online, Table S2).
For immunoblotting experiments, human and rat RV total protein was
extracted and separated in a 10% SDS–PAGE gel, electroblotted into
nitrocellulose membrane, and probed for primary antibodies (see
Supplementary material online, Table S3). After washing, the membrane
was probed with secondary antibodies (Li-COR Biosciences) and visual-
ized using an Odyssey scanner (Li-COR Biosciences). Human RV
CRHR2 expression was quantified using a horse-radish peroxidase con-
jugate secondary antibody (Bio-Rad) and ChemiDoc system, and nor-
malized for total protein content (Amido Black, Sigma Aldrich).
Blood collected from rats and humans was centrifuged and dispensed
plasma assayed for Ucn-2 concentrations using solid-phase sandwich
enzyme-linked immunosorbent assay according to manufacturer’s
instructions (SEC585Ra and SEC585Hu, Cloud-Clone Corp.).
2.11 Statistical analysis
The results are presented as the mean ± S.E.M. Survival analysis was per-
formed in R (version 3.4.1) using PwrGSD package (version 2.0),
whereas GraphPad Software v7 (GraphPad Software Inc., San Diego,
CA, USA) was used in all other parameters. Two-way analysis of var-
iance (ANOVA), with repeated-measures when suitable, was used to
analyse most parameters with Tukey’s method for post hoc comparisons
between groups. Where appropriate, Student t-test or one-way
ANOVA with Tukey’s method for post hoc comparisons were used.
Survival analysis was estimated according to the Kaplan-Meier method
and comparisons were performed using a generalized Fleming-
Harrington test (p = 1, q = 1) for non-proportional hazards, which gives
more weight to later events. A P-value of <0.05 was considered to be
statistically significant.
3. Results
3.1 Levels of Ucn-2 and CRHR2 are altered
in PAH-induced RVF and are modulated by
chronic hUcn-2 treatment
Plasma concentrations of Ucn-2 were unchanged in human PAH com-
pared with controls (Figure 1A). Measurement of Ucn-2 mRNA levels
in the RV of PAH patients with RVF showed increased expression
compared with non-failure patients (Figure 1B), whereas CRHR2 pro-
tein levels were found to be elevated in human PAH (Figure 1 and D).
There were no differences between male and female patients on both
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..plasma and RV mRNA Ucn-2 (see Supplementary material online,
Figure S1). Plasma concentrations of Ucn-2 were increased in MCT-
induced PH compared with controls, and hUcn-2 therapy in control
and MCT rats did not chronically increase the Ucn-2 plasma concen-
trations (Figure 1E). MCT animals treated with hUcn-2 showed a
reversal of RV Ucn-2 and CRHR2 mRNA expression to control levels
compared with the MCT group without treatment, which were ele-
vated (Figure 1F and G). Although there were no significant differences
in MCT group, administration of hUcn-2 in control animals resulted in
an increased CRHR2 protein expression (Figure 1H and I). Indeed, the
CRHR2 receptor is present in cardiomyocytes from control and MCT
RV (see Supplementary material online, Figure S2).
However, as seen for Ucn-2 in the lungs from PAH patients (see
Supplementary material online, Figure S1), we did not find any differences
between the groups in the expression of Ucn-2 and CRHR2 in experi-
mental PAH (Figure 1 J–M).
3.2 Treatment with hUcn-2 decreases mor-
bidity and improved exercise capacity in
experimental PAH
In our experimental protocol (Figure 2A) we observed that the
mean bodyweight and gain of MCT-induced PH animals were signifi-
cantly reduced compared with control animals after 24 days.
Treatment with hUcn-2, while reducing bodyweight gain in
Figure 1 Levels of Ucn-2 and CRHR2 are altered in PAH-induced RVF and are modulated by chronic hUcn-2 treatment. (A) Plasma Ucn-2 concentrations
in patients with PAH (n = 10–14/group). (B and C) mRNA expression of Ucn-2 and CRHR2 protein levels in the RV of patients with CRV and RVF. (D)
Representative blots of CRHR2 immunoreactivity in human RV samples (n = 8/group). (E) Plasma Ucn-2 concentrations in control and MCT-injected rats
with (CU/MU) and without (C/M) hUcn-2 treatment (n = 6–7/group). (F and G) mRNA expression of Ucn-2 and CRHR2 in the RV of MCT-induced PH pro-
tocol (n = 6–7/group). (H and I) CRHR2 protein levels in the RV of MCT-induced PH protocol and corresponding representative blots of CRHR2 immunor-
eactivity (n = 5–9/group). (J and K) mRNA expression of Ucn-2 and CRHR2 in the lungs of MCT-induced PH protocol (n = 9–13/group). (L and M) CRHR2
protein levels in the lungs of MCT-induced PH protocol and corresponding representative blots of CRHR2 immunoreactivity (n = 4/group). Results are pre-
sented as the mean ± S.E.M. *P < 0.05 vs. CRV in (panels B and C). *P < 0.05,**P < 0.01 vs. C; #P < 0.05 vs. M in (E–H). Student t-test was performed to com-
pare groups in panels (A–C), while two-way ANOVA was used for all the other parameters presented.
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.control animals, increased bodyweight gain in MCT animals
(Figure 2C and D).
MU group showed a lower percentage of animals reaching
the defined end-point, which serves as a surrogate for clinical
worsening, and could potentially represent an improvement in late
mortality (Figure 2B). Treatment with hUcn-2 for 10 days also signifi-
cantly improved the exercise capacity, with increases seen in dis-
tance run and maximum rate of oxygen consumption (VO2max)
(Figure 2E and F).
3.3 hUcn-2 treatment reduces cardiac and
pulmonary arterial remodelling in
MCT-induced PH
In MCT animals, administration of hUcn-2 resulted in decreased
RV and pulmonary vascular remodelling (Figure 3A). hUcn-2 treat-
ment attenuated MCT-induced increases in both RV and right atrial
dilation (Figure 3B and C) as well as the RV weight normalized to left
ventricle plus septum weight (RV/LV þ S) (Figure 3D). Lung weight
normalized to tibia length (Lung/TL), was reduced by hUcn-2 treat-
ment compared with the MCT group (Figure 3E). This shows a
decrease of fluid build-up in the lungs, potentially as a result of
improved LV diastolic function (see Supplementary material online,
Figure S5) in treated animals. Animals with PAH and without
pharmacological intervention also presented increased cardiomyo-
cyte CSA, as well as fibrosis deposition (Figure 3F and G). hUcn-2
treatment normalized both cardiomyocyte size and fibrotic
tissue deposition. Pulmonary small artery (15–50 mm) remodelling
was also decreased in MU group, as measured by a decline in
mean lumen/total ratio and mean medial thickness (Figure 3H
and I). A detailed morphometric analysis to evaluate vascular
remodelling in all, small (15–50 mm) and medium (50–100 mm) pul-
monary arterioles can be found in Supplementary material online,
Figure S3.
3.4 hUcn-2 attenuates pulmonary endothe-
lial dysfunction and induces vasodilatory
effects in MCT-induced PH
Isolated pulmonary arterial rings pre-contracted with phenylephr-
ine (10-5 M), exhibited a vasodilation response when incubated
with hUcn-2 (10-9 to 5  10-7 M) (Figure 4A and B). In rings isolated
from MCT animals, although present, vasodilation was significantly
decreased, when compared with controls (Figure 4C). The vasodila-
tion response to hUcn-2 in both groups was independent of
the endothelium (see Supplementary material online, Figure S4).
Furthermore, pre-treatment with hUcn-2 (50 nM) attenuated
phenylephrine-induced vasoconstriction in pulmonary arterial
Figure 2 Effect of hUcn-2 on morbidity and exercise capacity. (A) Diagram of rat experimental MCT protocol. (B) Survival analysis in MCT-injected rats
(n = 47–54/group). (C and D) Mean body weight and bodyweight gain in Control and MCT-injected rats with (CU/MU) and without (C/M) hUcn-2 treat-
ment (n = 17–54/group). (E and F) Distance run and maximal oxygen consumption during endurance testing in all experimental groups (n = 4–7/group).
Results are presented as the mean ± S.E.M. *P < 0.05,**P < 0.01,***P < 0.001. For panel (B), Kaplan-Meier survival analysis was performed. Two-way
ANOVA repeated measures test were used for all the other parameters presented.
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Figure 3 Treatment with hUcn-2 attenuates RV and pulmonary vascular remodelling. (A) Representative echocardiographs (first line PSAX = parasternal
short axis view; second line A4C = apical four chamber view) of Control and MCT-injected rats with (CU/MU) and without (C/M) hUcn-2 treatment; inter-
ventricular septum hypertrophy and bowing shown by white arrow heads, and RV dilation by white double arrow. Representative haematoxylin and eosin
(H&E) and picosirius red staining of RV samples (third and fourth lines) and representative H&E staining of lung samples (fifth line) of all experimental groups.
Scale bars represent 50 mm (400 magnification) in H&E stainings, and 25 mm (200 magnification) in picosirius red staining. (B and C) RAA (right atrial
area) and RVEDD analysis (n = 8–17/group). (D and E) RV/LVþ S and Lung/TL ratio analysis (n = 17–29/group). (F andG) Cardiomyocyte CSA and RV fibro-
sis (n = 7–9/group). (H and I) Mean Lumen/Total ratio and mean medial thickness in small vessels (<50 mm) analysis (n = 5–11/group). Results are presented
as the mean ± S.E.M. *P < 0.05,**P < 0.01,***P < 0.001 vs. C; #P < 0.05,##P < 0.01,###P < 0.001 vs. M. Two-way ANOVA repeated measures test was used
for comparisons in panels (B and C), and two-way ANOVA was used for all the other parameters presented.
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..rings isolated from control animals, while there was no inhibitory
effect in the MCT group with hUcn-2 pre-treatment (50 and
500 nM) (see Supplementary material online, Figure S4). We
found compromised relaxation in a dose–response test to
acetylcholine in pulmonary arteries isolated from MCT animals
and treating animals with hUcn-2, while not changing
phenylephrine-induced maximal tension (data not shown), signifi-
cantly enhanced endothelial function, by increasing the maximal
response to acetylcholine (Figure 4D and E). Furthermore, hUcn-2
decreased the EC50 (Figure 4F), increasing receptor sensitivity to
acetylcholine.
3.5 MCT-induced RV dysfunction is attenu-
ated with hUcn-2 treatment
Pulmonary flow compromise with subsequent RV overload results in RV
dysfunction. Likewise, echocardiographic analysis revealed a deteriorated
pulmonary flow with the presence of mid-systolic notching (Figure 5A,
first panel) in the M group, where pulmonary artery acceleration time
normalized to ejection time ratio (PAAT/PAET) and pulmonary artery
velocity-time integral (PAVTI) were decreased (Figure 5B and C). TAPSE
was also decreased (Figure 5D). hUcn-2 therapy improved pulmonary
flow and increased TAPSE. RV catheterization showed that MCT-
induced PH resulted in RV dysfunction 3 weeks after MCT administration
(Figure 5E). hUcn-2 treatment reduced PVR (Figure 5F), and this resulted
in decreased RV end-systolic pressure (RVSP, Figure 5G), consistent
with lessened RV hypertrophy, RV dilation (end-diastolic volume, EDV,
Figure 5L) and RV dysfunction as shown by the increase of EF (Figure 5H)
and CO (Figure 5I). Additionally, hUcn-2 therapy attenuated diastolic dys-
function, with reduced filling pressures, improved relaxation, and
decreased diastolic stiffness, quantified by lower end-diastolic pressure
(RVDP, Figure 5J), reduced isovolumic relaxation time constant (tau,
Figure 5K), and decreased end-diastolic elastance (Eed, Figure 5M),
respectively. Additionally, treated animals demonstrated improved sys-
tolic function, with decreased arterial elastance (Ea) while preserving
contractility (Ees) resulting in improved RV-PA coupling (Ees/Ea)
(Figure 5N). Intrinsic diastolic RV function, as measured in isolated
skinned cardiomyocytes (Figure 5O), was also improved with hUcn-2
treatment, once the increase in passive tension at several sarcomeric
lenghts (Figure 5P) was attenuated in MU animals. Similar to the RV,
hUcn-2 treatment improved global LV function, recovering both systolic
and diastolic function (see Supplementary material online, Figure S5).
3.6 Molecular alterations in MCT-induced
PH are reduced with hUcn-2 treatment
Rats with MCT-induced PH displayed increased brain natriuretic pep-
tide (BNP) (Figure 6A) and endothelin-1 (ET-1) (Figure 6B) RV expres-
sion – peptides that are associated with cardiac overload and
hypertrophy. Moreover, increased expression of apoptotic markers,
Figure 4 Acute and chronic treatment with hUcn-2 results in improved pulmonary arterial function in MCT-induced PH. (A and B) Relaxation in isolated
pulmonary arterial rings from Control (C) and MCT-injected rats (M) pre-contracted with phenylephrine (10-5 M) in response to vehicle (Veh) and hUcn-2
(10-9 to 5 10-7 M; left panel). Black arrowhead on panel (A) represents incubation with 10-5 M of phenylephrine. (C) EC50 for hUcn-2 in C and M groups
(n = 7/group). (D and E) Relaxation in isolated pulmonary arterial rings from C, CU, M, and MU rats pre-contracted with phenylephrine (10-5 M) in response
to an acetylcholine dose-response (10-9 to 10-5 M; left panel). Black arrowhead on the panel (D) represents incubation with 10-5 M of phenylephrine.
(F) EC50 for acetylcholine in C, CU, M, and MU groups (n = 9–17/group). Results are presented as the mean ± S.E.M. **P < 0.01, ***P < 0.001 vs. line tar-
geted groups in panels (B and E). ***P < 0.001 vs. C; ##P < 0.01 vs. M in panels (C and F). Two-way ANOVA repeated measures was used for comparisons in
panels (B and E), while two-way ANOVA was used for panel (F). Student t-test was used for panel (C).
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..namely caspase-3 and caspase-8, was also observed in MCT animals
(Figure 6C). Treatment with hUcn-2 reduced the expression of these
markers of cardiac damage. The increase in RV fibrosis seen in MCT
rats was paralleled by augmented levels of RV collagen type III alpha 1
(Col3A1) mRNA (Figure 6D), which were reversed by hUcn-2 treat-
ment. In MCT-induced PH we also observed a shift towards b-myosin
heavy chain (MHC) mRNA amplification and corresponding decline
in aMHC, resulting in marked increase in the b/aMHC ratio in MCT
Figure 5 Treatment with hUcn-2 attenuates RV dysfunction in MCT-induced PH. (A) Representative figures of the echocardiographic analysis. (B–D)
PAVTI, PAAT/PAET, and TAPSE analysis. (E) Representative pressure–volume loops of the different experimental groups. (F–N) PVR, RVSP, EF, CO, RVDP,
Tau, end-diastolic volume, end-diastolic stiffness (Eed), and end-systolic elastance normalized to pulmonary artery elastance (Ees/Ea) ratio analysis in all
experimental groups (n = 10–18/group). (O and P) Representative single isolated skinned cardiomyocyte and passive tension (PT) in cardiomyocytes isolated
from the RV of all groups (n = 10–18/group, n 30cardiomyocytes/group). Results are presented as the mean ± S.E.M. *P < 0.05,**P < 0.01,***P < 0.001 vs.
line targeted groups (panels B–D) and vs. C in panels (F–N and P); #P < 0.05; ##P < 0.01; ###P < 0.001 vs. M in panels (F–N) and vs. MU in panel (P). Two-way
ANOVA repeated measures test was used for comparisons in panels (B–D and P), while two-way ANOVA was used for all the other parameters presented.
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animals (Figure 6E). hUcn-2 therapy completely reversed the shift in
MHC isoform expression. Furthermore, impaired RV function in
MCT animals, underlined by decreased CO and RV perfusion,
resulted in the up-regulation of hypoxia-inducible factor 1-alpha
(HIF-1a) mRNA (Figure 6F), and again, hUcn-2 administration abol-
ished this increase. Western blot analysis showed reduced activation
of downstream mitogen-activated protein kinase (MAPK) pathways
in the MCT group, with decreased phosphorylation of p-42/44 and
p38 proteins. Chronic treatment with hUcn-2 restored the levels of
these proteins (Figure 6G). The apoptotic bcl-2 like protein-4 normal-
ized to B-cell lymphoma 2 (Bax/Bcl-2) ratio was increased in the MCT
group, and treatment with hUcn-2 also abolished this rise (Figure 6H).
Moreover, pro-survival signalling in the RV was diminished in
MCT-induced PH, with decreased protein phosphorylation of
Figure 6 Chronic hUcn-2 treatment attenuates molecular alterations in experimental PAH-induced RVF. (A–F) BNP, ET-1, caspase-3 and -8, Col3A1,
MHC, and HIF-1a mRNA expression in the RV of Control and MCT-injected rats with (CU/MU) and without (C/M) hUcn-2 treatment (n = 5–7/group). (G)
Protein phosphorylation of p42/44 (Thr202/Tyr204) and p38 (Thr180/Tyr182) in the RV of all groups. (H and I) Analysis of pro-survival pathways in the RV
of all experimental groups, with Bax/Bcl-2 ratio and phosphorylation of Akt (Ser473), GSK-3b (Ser9), and STAT3 (Tyr705) (n = 6–8/group). Results are pre-
sented as the mean ± S.E.M. *P < 0.05,**P < 0.01,***P < 0.001 vs. C; #P < 0.05; ##P < 0.01; ###P < 0.001 vs. M. Two-way ANOVA was used for all
comparisons.
Urocortin-2 attenuates pulmonary arterial hypertension 1173
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/article-abstract/114/8/1165/4951951 by U
niversidade do Porto user on 16 O
ctober 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..glycogen synthase kinase 3 beta (GSK3b) and signal transducer and
activator of transcription 3 (STAT3), which was reversed by hUcn-2.
No differences were observed in protein kinase B (AKT) phosphory-
lation (Figure 6I).
3.7 hUcn-2 treatment attenuated
PAB-induced RV hypertrophy
Using the PAB model (Figure 7A), the therapeutic effects of hUcn2 on
the RV, independent from its action on the pulmonary vasculature, were
investigated. PAB resulted in RV dilation, as judged by an increase in right
ventricle end-diastolic dimension (RVEDD) (Figure 7E), hypertrophy, as
evidenced by a higher RV/LVþ S ratio (Figure 7F), and increased cardio-
myocyte CSA (Figure 7G) and fibrosis (Figure 7H). hUcn-2 decreased
RV hypertrophy and fibrosis relatively to untreated animals with the
same degree of constriction (similar pulmonary artery gradient,
Figure 7D), without compromising cardiac function (Figure 7C and see
Supplementary material online, Figure S6). Finally, treatment with hUcn-2
attenuated the increase in passive stiffness observed in animals with PAB
(Figure 7I).
Figure 7 Chronic treatment with hUcn-2 decreases RV hypertrophy and fibrosis secondary to RV pressure overload. (A) Diagram depicting the PAB
experimental protocol. (B) Representative echocardiographs (first line PSAX, parasternal short axis view; second line A4C, apical four chamber view), show-
ing interventricular septum (white arrow heads) and RV diameter (white double arrow) in Sham and PAB rats with (BU) and without (S/B) hUcn-2 treat-
ment. Representative H&E and picosirius red staining of RV samples (third and fourth lines) of all groups. Scale bars represent 50 mm (400magnification) in
H&E staining, and 25 mm (200magnification) in picosirius red staining. (C) CO analysis in all groups. (D) Pulmonary artery gradient (PAG) across the PAB in
both banding groups. (E and F) RVEDD and RV/LV þ S ratio analysis. (G and H) RV cardiomyocyte CSA and RV fibrosis analysis in all groups (n = 7–12/
group). (I) Passive tension (PT) in cardiomyocytes isolated from the RV of all groups (n = 7–12 rats/group, n 30 cardiomyocytes/group). Results are pre-
sented as the mean ± S.E.M. *P < 0.05,**P < 0.01,***P < 0.001 vs. S; #P < 0.05; ##P < 0.01 vs. B in panels (F–H) and vs. BU in panel (I). One-way ANOVA
repeated measures test was used for comparisons in panels (I), while one-way ANOVA was used for all the other parameters presented.
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4. Discussion
This study evaluated the expression of the Ucn-2/CRHR2 system in
PAH and investigated the effect of hUcn-2 treatment in experimental
PAH and RV hypertrophy. We found that Ucn-2 expression was
increased in the RV of MCT–injected rats and patients with RVF, and
that chronic hUcn-2 therapy attenuated experimental MCT-induced PH,
as evidenced by beneficial effects on morbidity, exercise capacity and
pulmonary and RV remodelling and dysfunction. Additionally, hUcn-2
treatment had direct effects on RV structure and function in a model of
pressure loading of the RV without PAH.
Recent studies in experimental HF have shown favourable effects of
Ucn-2 treatment in pacing-induced HF,13,14,32,33 myocardial infarction15
and systemic hypertension.24 Beneficial effects in healthy volunteers and
patients with acute17 and chronic HF16,34 have further excited interest in
the therapeutic potential of the urocortins, although whether or not the
increased Ucn-2 circulating levels is a cardioprotective response is yet to
be understood.
Our results show elevated RV expression and plasma concentrations
of Ucn-2 in MCT-induced PH, possibly in response to myocardial stress.
Inversely, there was a decrease in CRHR2 mRNA levels in the RV, as
observed in HF.35 Interestingly, CRHR2 protein expression in MCT was
increased in the RV. This mRNA/protein mismatch suggests a down-
regulation of CRHR2 mRNA that precedes any decline in CRHR2 pro-
tein expression, possibly due to a decrease in receptor endocytosis.36 In
adipose tissue from animals subjected to hypoxia, both CRHR2 mRNA
and protein levels are increased acutely, and while receptor protein
expression remains elevated over 10 days post-hypoxia, CRHR2 mRNA
expression gradually decreases to pre-hypoxia levels by day 10.37 In
human RVF, we found an increase of Ucn-2 mRNA and CRHR2 protein
expression compared with the non-failing RV, similarly to our animal
model. We were unable to find significant differences in the plasma levels
of Ucn-2 in human PAH. Only three studies have measured plasmatic
Ucn-2 levels in human patients with cardiovascular disorders, reporting
significantly different (up to 1000-fold) concentrations in their
cohorts.18–20 However, Ucn-2 seems to be activated on circulating and
inflammatory cells (buffy coat), which mediate vascular and myocardial
remodelling mechanisms.38 Also, we did not find any differences in the
lung expression of Ucn-2 and CRHR2 in experimental PAH, suggesting a
more profound dysregulation of Ucn-2/CRHR2 signalling in the RV as
compared with the lung.
Despite the gender differences observed in other peptides from the
Ucn family and CRHR2,39–41 there were no gender-related differences
in plasma Ucn-2 levels in patients with heart disease,19,21 nor in the role
of CRHR2 in HF.20 This was also true in our small cohort of patients.
We next analysed the effects of chronic hUcn-2 therapy in MCT-
induced PH, and observed improvements in weight gain in the MU
group, paralleled by an increase in exercise capacity, suggesting an inte-
grated protective effect of hUcn-2 in the cardiovascular system and skel-
etal muscle. Exercise capacity, evaluated clinically by the 6-min walk test,
and emulated here by exercise capacity testing, integrates the function of
the whole cardiopulmonary system and has strong prognostic signifi-
cance.1 Also, disease progression is associated with increased mortality
in PAH, and contains major prognostic relevance,42 therefore our find-
ings that a lower percentage of MU rats achieved the defined end-points
suggests a positive effect on future mortality.
Some of the beneficial Ucn-2 effects in HF result from direct actions
on cardiomyocytes, however, they may be more pleiotropic.8 Indeed,
hUcn-2 treatment resulted in the attenuation of both RV and pulmonary
vascular remodelling. RV dilation and hypertrophy were significantly
reduced with hUcn-2 treatment, in association with decreased cardio-
myocyte size and RV fibrosis. These results are consistent with recent
observations in which Ucn-2 reduced post-infarct remodelling,15 and
retarded the development of hypertension-induced LV hypertrophy.24
Similarly, decreased pulmonary arterial small artery remodelling after
hUcn-2 treatment led to a reduction in PVR and RV afterload, which
explains, in part, the reduction in RV remodelling.
The observed RV dysfunction in MCT rats is consistent with decom-
pensated RV hypertrophy, where compromised systolic flow is associ-
ated with elevated RVSP and correlates with decreased survival in
PAH.43 In MCT-induced PH, hUcn-2 improved pulmonary arterial flow
and decreased RV afterload. TAPSE, an indicator of RV contractile func-
tion, was also improved. MCT-injected animals exhibited severe cardiac
dysfunction, with compromised CO, EF and increased RVSP, which
were both ameliorated by hUcn-2. We also observed that MCT-induced
PH was associated with RV-PA uncoupling, due to an insufficient increase
in contractility to match the increase in afterload.44 Abnormal RV-PA
coupling is a major determinant of RV HF and one of the leading causes
of death in PH,45 and its evaluation may help identify at-risk-patients or
guide the timing of therapeutic interventions in PAH.46 Remarkably,
hUcn-2 decreased pulmonary elastance (Ea) without compromising RV
contractility (Ees), resulting in an improved RV-PA coupling. Diastolic
dysfunction was also attenuated by hUcn-2, as shown by decreased stiff-
ness and RV diastolic elastance. At the cellular level, hUcn-2 reduced
passive tension measured in isolated RV cardiomyocytes, contributing to
the decreased stiffness and improved diastolic function observed.
Additionally, we observed an acute effect of hUcn-2 in modulating pul-
monary artery vasomotor status, which probably contributed to a
change in PVR. Several endothelium-independent and -dependent
mechanisms have been proposed to describe Ucn-2-mediated
vasodilation.22,23,47 Our analysis of acute hUcn-2 effects in pulmonary
arterial rings from MCT-injected animals demonstrated a significant
endothelium-independent vasodilatory effect, although attenuated when
compared with control vessels. This can be an advantage in PAH which
is associated with impaired endothelial homeostatic mechanisms.
Furthermore, Ucn-2 induces a potent prolonged arterial vasodilatation
without causing significant tachyphylaxis,23 which is important especially
when considering its potential application as a chronic PAH therapy.
Myocardial remodelling, increased wall stress, hypoxic damage and
apoptosis in MCT-induced PH are correlated with increased RV mRNA
expression of damage markers,28,48 which was reduced by hUcn-2 ther-
apy, either by directly acting on these signalling pathways, or indirectly by
attenuating RV dysfunction. Moreover, the decreased phosphorylation
of both ERK 1/2 and p38 MAPK likely relates to the advanced stage of
HF49 in our model, and its activation by hUcn-2,50 may be a preventive
mechanism. Akt was not affected by any drug administered (MCT/hUcn-
2), as previously reported in.51 Increased STAT3 and GSK3b phosphory-
lation and reduced Bax/Bcl-2 ratio in MU rats match what has been
previously described in vitro,52,53 demonstrating the cardioprotective
Ucn-2 proprieties.
Recently, it was demonstrated that plasma Ucn-2 levels significantly
increase in human and experimental LVHF. Additionally, continuous
CRHR2 agonist infusion (100lg/kg/day during 4 weeks) in control mice
increased plasma Ucn-2 in a similar degree to that observed in mice with
pressure overload–induced HF, resulting in cardiac dysfunction without
having a significant effect on systolic blood pressure.20 These findings
suggest that higher doses of chronic Ucn-2 administrations without vaso-
relaxation may have cardiotoxic effects, activating chronically the PKA,
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CaMKII, and AKT signalling pathways. In our experimental study,
although Ucn-2 therapy modulated Ucn-2/CRHR2 expression in the RV,
there was no significant increases in plasmatic Ucn-2, which could impair
cardiac function.
The Ucn-2 effects can be explained by pulmonary vascular mechanisms;
however, it was unclear whether hUcn-2 has any myocardial-specific
effects. Indeed, there is some concern over data suggesting that the Ucn-2
may induce hypertrophic responses in cardiac myocytes.20 Thus, similarly
to a previous work by our group,28 we decided here to use a mild PAB
model, as it better replicated the degree of overload observed in MCT-
induced PH, without pulmonary vascular involvement.29 Other works
showed that adapted RVs with increased afterload but with compensated
function have significant RV structural changes54–57; however, specific
comparisons with this model can be difficult to make, as significant varian-
ces can be obtained in different conditions. Interestingly, hUcn-2 attenu-
ated RV hypertrophy and fibrosis, without compromising function,
indicating that hUcn-2 has a direct effect on the RV contributing to the
improved RV function observed in MU animals, at least in hUcn-2 dose
used in MCT protocol. As in the MCT model, constriction of the pulmo-
nary artery promotes not only structural changes, but also intrinsic altera-
tions.29,58 Interestingly, hUcn-2 decreased passive tension development,
contributing directly to attenuation of diastolic dysfunction in these ani-
mals, which could be the tipping point for RVF in PAH.58
One limitation of our work is the lack of categorization of PAH
patients accordingly to their RV phenotype with an individualized clinical
follow-up. Indeed, the low levels of plasma Ucn-2 may relate to a CRV
state in these patients. However, there is an association between Ucn-2/
CRHR2 expression and RV dysfunction. In the experimental setting, the
limitations include the lack of investigation of subcellular mechanisms
underlying the actions of Ucn-2 in the pulmonary vasculature, and this
should be the subject of further research. Although not all characteristics
of PAH are simulated by the MCT model, it shares many characteristics
with primary and secondary human PH, including pulmonary vascular
remodelling, and RV and endothelial dysfunction38 and hUcn-2 amelio-
rated most of these parameters. Additionally, at 14 days after MCT
administration animals exhibit RV hypertrophy, vascular remodelling,
and pulmonary flow compromise, suggesting that hUcn-2 reverses
already established PAH, which is clinically important.1 Also, LV dysfunc-
tion which is present in advanced stages of PAH59 was attenuated by
hUcn-2, underscoring the putative translational implication. In PAB pro-
tocol, the underlying mechanisms of the myocardial-specific effects in RV
should as well be a subject of further study.
In conclusion, this study demonstrated that Ucn-2/CRHR2 signalling
has an important role in PAH and RV dysfunction, given that levels of
Ucn-2 and its receptor are altered in human and experimental PAH.
Additionally, hUcn-2 treatment improves cardiopulmonary structure
and function, once it attenuates PAH and RV dysfunction in MCT-
induced PH, has direct anti-remodelling effects on the pressure-
overloaded RV, and improves pulmonary vascular function.
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